StockData
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3084% below fair value
$1.05−0.02 (-1.87%)

Close on Nov 20, 2026Market cap $33.01MP/E 2.9Yield –

Actinium Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Actinium Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2024 was -$33.08M. For fiscal 2025 it was -$24.68M. The highest annual figure on record is $8.28M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$24.68M–
FY2024Dec 31, 2024-$33.08M–
FY2023Dec 31, 2023-$47.49M-673.7%
FY2022Dec 31, 2022$8.28M–
FY2021Dec 31, 2021-$21.00M–
FY2020Dec 31, 2020-$21.87M–
FY2019Dec 31, 2019-$21.53M–
FY2018Dec 31, 2018-$20.67M–
FY2017Dec 31, 2017-$21.58M–
FY2016Dec 31, 2016-$20.85M–
FY2015Dec 31, 2015-$18.59M–
FY2014Dec 31, 2014-$14.50M–
FY2013Dec 31, 2013-$6.31M–
FY2012Dec 31, 2012-$5.22M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.66M–
Q1 FY2026Mar 31, 2026-$5.87M–
Q4 FY2024Dec 31, 2024-$5.75M–
Q3 FY2024Sep 30, 2024-$11.98M–
Q2 FY2024Jun 30, 2024-$7.97M–
Q1 FY2024Mar 31, 2024-$7.39M–
Q4 FY2023Dec 31, 2023-$7.49M–
Q3 FY2023Sep 30, 2023-$11.16M–
Q2 FY2023Jun 30, 2023-$13.69M-149.5%
Q1 FY2023Mar 31, 2023-$15.15M–
Q4 FY2022Dec 31, 2022-$7.79M–
Q3 FY2022Sep 30, 2022-$5.79M–
Q2 FY2022Jun 30, 2022$27.65M–
Q1 FY2022Mar 31, 2022-$5.79M–
Q4 FY2021Dec 31, 2021-$5.05M–
Q3 FY2021Sep 30, 2021-$5.66M–
Q2 FY2021Jun 30, 2021-$4.65M–
Q1 FY2021Mar 31, 2021-$5.65M–
Q4 FY2020Dec 31, 2020-$6.50M–
Q4 FY2019Dec 31, 2019-$5.02M–
Q3 FY2019Sep 30, 2019-$5.60M–
Q2 FY2019Jun 30, 2019-$5.37M–
Q1 FY2019Mar 31, 2019-$5.54M–
Q4 FY2018Dec 31, 2018-$4.30M–
Q3 FY2018Sep 30, 2018-$6.67M–
Q2 FY2018Jun 30, 2018-$4.23M–
Q1 FY2018Mar 31, 2018-$5.47M–
Q4 FY2017Dec 31, 2017-$3.17M–
Q3 FY2017Sep 30, 2017-$5.88M–
Q2 FY2017Jun 30, 2017-$7.15M–
Q1 FY2017Mar 31, 2017-$5.38M–
Q4 FY2016Dec 31, 2016-$4.26M–
Q3 FY2016Sep 30, 2016-$5.57M–

More Actinium Pharmaceuticals figures

See a number that looks wrong?